Neurosterix
The startup develops allosteric modulator therapies that target receptors outside the active site to treat neurological disorders. Its drug discovery platform enhances the efficacy, safety, and tolerability of treatments for patients with underserved neurological conditions.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
Funding
Raised to date
$170MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
$105M · Series B
Announced Nov 2026 · from article date
Disclosed cumulative: $170M
Founders
Founder details are not available yet.
Product
Problem
Neuropsychiatric disorders such as schizophrenia, mood, and anxiety conditions remain among the most urgent and underserved areas of medicine. Current treatments often provide only partial relief, blunting symptoms without restoring healthy brain function, while many patients endure delayed and limited treatment benefits along with significant side effects.
Solution
Neurosterix develops next-generation allosteric modulator therapies that fine-tune brain signaling with precision, acting like dimmer switches rather than on/off switches to restore balance in neural circuits. The company's proprietary discovery platform combines innovative medicinal chemistry, deep receptor pharmacology, and advanced screening technologies to generate novel allosteric modulators that precisely modulate brain circuits. These modulators bind to distinct allosteric sites rather than the active orthosteric site, enabling enhanced target specificity, reduced off-target interactions, and improved safety and tolerability compared to traditional drugs. Neurosterix is advancing a focused pipeline of first- and best-in-class programs targeting key brain receptor systems for psychosis, mood, and anxiety disorders.
Target Audience
Primary customers are patients with high-burden neuropsychiatric conditions including schizophrenia, psychosis, mood, and anxiety disorders, as well as healthcare providers and payers seeking treatments with improved efficacy, safety, and tolerability compared to existing options.
Features
- Lead program NTX-253 (M4 PAM) has completed Phase 1 single- and multiple-ascending-dose clinical studies and is advancing into Phase 2 for schizophrenia
- Pipeline includes NTX-529 (best-in-class M4 PAM) for schizophrenia and NTX-819 (first-in-class mGlu7 NAM) for mood and anxiety disorders
- Discovery engine built on an 80,000+ compound library and 200+ CNS-relevant functional assays specifically designed to detect and characterize allosteric modulators
- Nearly 20 successful high-throughput screening campaigns conducted across muscarinic, glutamatergic, and other receptor families
- Proprietary expertise in positive allosteric modulators (PAMs) that amplify signaling and negative allosteric modulators (NAMs) that dampen excessive receptor activity
- 100+ patents and 30+ peer-reviewed publications supporting the science of allosteric modulation